TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 65.4% in December

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 31,600 shares, a growth of 65.4% from the November 30th total of 19,100 shares. Based on an average daily volume of 1,650,000 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their target price on shares of TC Biopharm from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, December 6th.

TC Biopharm Stock Performance

TCBP stock remained flat at $0.71 during midday trading on Friday. The company’s stock had a trading volume of 676,019 shares, compared to its average volume of 623,716. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.12 and a quick ratio of 0.88. The stock’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $4.63. TC Biopharm has a fifty-two week low of $0.44 and a fifty-two week high of $41.50.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.